Show simple item record

dc.creatorGutiérrez, José María
dc.creatorLomonte, Bruno
dc.creatorSanz, Libia
dc.creatorCalvete Chornet, Juan José
dc.creatorPla Ferrer, Davinia
dc.date.accessioned2014-04-08T22:15:07Z
dc.date.available2014-04-08T22:15:07Z
dc.date.issued2014-02-28
dc.identifier.citationhttp://www.sciencedirect.com/science/article/pii/S1874391914000700es
dc.identifier.issn1874-3919
dc.identifier.otheressn:1876-7737
dc.identifier.urihttp://hdl.handle.net/10669/11041
dc.descriptionartículo (arbitrado) -- Universidad de Costa Rica, Instituto de Investigaciones Clodomiro Picado. 2014. este documento es privado debido a limitaciones de derechos de autor.es
dc.description.abstractParenteral administration of animal-derived antivenoms constitutes the mainstay in the treatment of snakebite envenomings. Despite the fact that this therapy has been available for over a century, the detailed understanding of the neutralizing and immunoreactivity profiles of the majority of antivenoms is pending. Currently, a combination of preclinical neutralization tests and ‘antivenomics’, i.e. a proteomic-based assessment of antivenom immunoreactivity, provides a powerful analytical platform to investigate the preclinical efficacy of antivenoms. In this review, the studies performed on the polyvalent antivenom manufactured by Instituto Clodomiro Picado, Costa Rica, are summarized. This antivenom is prepared by immunizing horses with a mixture of the venoms of Bothrops asper, Crotalus simus and Lachesis stenophrys, and is used in Central America for the treatment of envenomings by viperid species. Overall, the antivenom shows a widespread pattern of immunological reactivity against homologous and heterologous venoms, which correlates with its ability to neutralize lethal, hemorrhagic, myotoxic, coagulant, defibrinogenating, phospholipase A2 and proteinase activities of viperid venoms. At the same time, antivenomics detected several venom components against which the antivenom shows only partial or negligible immunorecognition, such as low molecular mass vasoactive peptides, disintegrins, and some phospholipases A2, P-I metalloproteinases and serine proteinases. Such information can be used to design strategies for enhancing the antibody response of horses against poorly immunogenic, toxicologically-relevant venom components in order to further improve the efficacy of this antivenom.es
dc.description.sponsorshipUniversidad de Costa Ricaes
dc.language.isoen_USes
dc.publisherEn prensaes
dc.subjectAntivenenoes
dc.subjectAntivenomes
dc.subjectVeneno de serpientees
dc.subjectSnake venomes
dc.subjectSustancia peligrosaes
dc.subjectVenomicses
dc.titleImmunological profile of antivenoms: preclinical analysis of the efficacy of a polyspecific antivenom through antivenomics and neutralization assayses
dc.typeinfo:eu-repo/semantics/articlees
dc.typeArtículo científicoes
dc.identifier.doi10.1016/j.jprot.2014.02.021
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP)es


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record